Although commercial payers consistently provide coverage of the more-well-established BRCA1/2 and Lynch syndrome panels, their perspectives on coverage of expanded panels are generally negative with only a few plans supportive of coverage and often, coverage is linked to performance at a preferred lab. This evidence concerns the gene BRCA1 and Lynch syndrome.